| Anna Johansson on Wed, 19 Feb 2003 05:07:01 +0100 (CET) |
[Date Prev] [Date Next] [Thread Prev] [Thread Next] [Date Index] [Thread Index]
| [Nettime-bold] BSG BioNewsLetter 04#2003 - Health Economics - Colon - Swedish Market - Osteoporosis - OTC - BioSeeker Group's analysis and products eNewsletter |
Attachments: BSG BioNewsLetter 04#2003 - BioSeeker Group's analysis and products eNewsletter URL: http://www.bioseeker.com http://www.bsg-online.biz -- CONTENTS -- 1) New Report: 'Health Economics in the Drug Life Cycle' 2) New Report: 'The Pharmaceutical Portfolio Management Outlook' 3) New Report: 'The OTC Outlook to 2007' 4) New Report: 'Winning the Osteoporosis Therapy Race' 5) New Report: 'Market and Sales Guide to the Swedish Biotechnology Market' 5) Recently Published BioSeeker Reports 6) Coming reports: Immunotherapy Strategies 7) Subscription ==================================================================== 1) Health Economics in the Drug Life Cycle - Achieving success in drug discovery, development, reimbursement and marketing The increasingly cost-conscious nature of formulary decisions and the willingness of reimbursers to reject a drug for listing on budget impact grounds means that drug companies must address the issue of affordability at a very early stage in the drug development process. If correctly applied, health economics techniques will deliver a product unit price which creates a win-win situation between the manufacturer and the purchaser or prescriber of the drug, thus ensuring early product reimbursement, rapid product uptake and maximum market share. For more information, please visit http://www.bioseeker.com/index.asp?report=health_economics ==================================================================== 2) The Pharmaceutical Portfolio Management Outlook The application and definition of portfolio management has evolved greatly over the past 20 years. The impact of rising R&D costs and falling productivity levels has led companies to pay far greater attention to their portfolio strategies, resource allocation and decision-making. Today, no major pharmaceutical or biotechnology company is without some centralized portfolio management function with wide ranging responsibilities including strategy development, investment appraisal and resource allocation. However, those most affected by portfolio management continue to be the executives in R&D and marketing with the responsibility to deliver successful projects and leading products in order to generate the high levels of return on investment required by shareholders. The new management report Pharmaceutical Portfolio Management: Integrated decision-making in marketing and R&D, presents a comprehensive overview of effective portfolio management processes, with a focus on better ! preparing senior management, R&D and marketing executives for integrated decision-making across the organization as a whole. Utilise this new report to improve product lifecycle decisions and ensure the right people are involved in making the right decisions, at the right time. Effective portfolio management will generate greater efficiencies, reduce costs and will ultimately increase profits. For more information, please visit http://www.bioseeker.com/index.asp?report=pharma_portfolio ==================================================================== 3) The OTC Outlook to 2007 The impending expiry of the patents covering 18 major prescription drugs has encouraged pharmaceutical companies to look towards the OTC market for revenue protection and lifecycle extension for their major products. Although certain sectors of the OTC market are maturing, growth opportunities do exist in emerging markets, possible product switches and novel indications. As self-medication is more widely adopted and healthcare payers seek to contain costs, the OTC market seems set for significant future growth. The OTC Outlook to 2007, a new management report by Reuters Business Insight, analyses the recent performance of the OTC markets in the US, Japan, Germany, the UK and France. Market data is allied to an evaluation of strategies, trends and growth drivers to forecast future revenue potential in therapeutic and national markets and growth opportunities are identified for all companies throughout OTC sectors. For more information, please visit http://www.bioseeker.com/index.asp?report=otc_outlook ==================================================================== 4) Winning the Osteoporosis Therapy Race At present we are witnessing a significant change in the osteoporosis therapy market. As is most often the case in a developed pharmaceutical market, this change takes the form of a shift, not a revolution. The bisphosphonates will remain the leading drug class, with a distinct move to oral dosing at weekly intervals, and/or intravenous dosing at yearly, or at least quarterly, intervals. There remains little to be improved in terms of potency of drugs in this class, and so most efforts Ð including those of the generic competitors which will increasingly emerge during the next few years Ð will be directed to better bioavailability and tolerability. For more information, please visit http://www.bioseeker.com/index.asp?report=osteoporosis ==================================================================== 5) Market and Sales Guide to the Swedish Biotechnology Market This is the first and only market and sales guide to the biotech industry in Sweden. It is now possible for you to decide whether the Swedish biotech industry or any segment of it may be of potential value for your business purposes. We provide you with information important for deciding on the Òbuying powerÓ of each of the 13 industry segments and each of the 300 companies included in this report. Up to 3 years of financial data from public as well as private companies is included. The report is structured around 13 industry segments. In each segment we review development; geographical distribution; latest developments; the segment vs. total market development; and key financial figures such as employees, turnover, expenditures, sales, revenues, total current assets, revenues, assets-to-debts-ratio, solidity, labor costs in percent of total expenditures. For more information, please visit http://www.bioseeker.com/index.asp?report=swebiotech_sales ==================================================================== 5) RECENTLY PUBLISHED BIOSEEKER REPORTS - Advancements in Colon Cancer Therapeutics (released Jan, 2003) http://www.bioseeker.com/index.asp?report=coloncancer - Molecular Approaches towards HCV Therapy - The Complete Guide (released Dec, 2002) http://hcv-therapeutics.info - Ion Channels as Therapeutic Targets for Multiple Diseases (released Nov, 2002) http://www.bioseeker.com/index.asp?report=ionchanneltargets - New Targets and Drug Discovery Platforms in Antifungal R&D (released Nov, 2002) http://www.bioseeker.com/index.asp?report=antifungal2 - The Next Generation Antifungals: Triazoles vs. Peptides http://www.bioseeker.com/index.asp?report=antifungal (released Oct, 2002) - Swedish Biopharma Industry - The Next Wave (released Sept, 2002) http://www.swedishpharma.info =================================================================== 6) COMING REPORTS - A Shift in Cancer Immunotherapy Strategies? Immunotherapy has for some time been tried as a breakthrough approach for cancer treatment, but failed. More simple protocols are now changed for more sophisticated ones, and even now novel solutions are emerging. Recent insights into the cells, molecules and signalling pathways that regulate immune responsiveness are providing new approaches for immunotherapy. And new insights have suggested that it might be beneficial to begin tumour immunotherapy soon after the completion of chemotherapy to induce effective homeostatic T-cell proliferation. This report evaluates the latest advancements in cancer immunotherapy as well as describes key company activities. BioSeeker Group is monitoring a lagre number of companies working in this field for the possibility of generating highly updated analysis. For more information about this report, please contact us at bioinfo@bioseeker.com - Guide to European Biotechnology Venture Capital Market This report is meant as a guide for biotech companies seeking venture capital investors. Trends, developments, preferences of the largest Pan-European investors and useful forums for meeting VC investors will be discuessed. The report also includes an extensive list of VC investors for which we list their financial strength and preferences. This report will be of great value to you as your company plans its VC attraction campaign. For more information, please contact us at bioinfo@bioseeker.com ==================================================================== 7) SUBSCRIPTION To continue to stay tuned with coming editions of BioSeeker Groups free BioNewsLetter, please send an email to subscribe@bioseeker.com ============================================================================ BIOSEEKER ONLINE STORE BioSeeker has made it easy to order any of our products online, directly from our website. Visit www.bsg-online.biz to place an online order. ADVERTISING Do you have a message that you would like the biotech community to know? BioSeeker Group's Newsletter targets managers, scientists, venture capitalists, consultants and many more world wide. Contact us at sales@bioseeker.com for further information on how to advertise in BSG BioNewsletter. COURTESY If you would like to comment on our newsletter please send us an email to feedback@bioseeker.com If you would like to be removed from our newsletter list, please reply to unsub@bioseeker.com You have received this newsletter to the address nettime-l@bbs.thing.net _______________________________________________ Nettime-bold mailing list Nettime-bold@nettime.org http://amsterdam.nettime.org/cgi-bin/mailman/listinfo/nettime-bold